16 Stocks Jim Cramer Recently Talked About
“I want you to keep in mind that September is a pivotal month for the sportsbooks because it marks the start of the football season. It's make or break for these companies….
Uniqure N.v. (QURE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 3,988,971 | $55,606,256 | 3.29% | |
| 2. | Vestal Point Capital Ryan Wilder | 3,700,000 | $51,578,000 | -23% | 2.72% |
| 3. | VenBio Select Advisor Kurt Von Emster | 3,625,000 | $50,532,500 | +67% | 0.88% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 2,095,931 | $29,217,278 | 0.25% | |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,051,852 | $28,602,817 | -26% | 1.12% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.10 | 60,000 | $2,706,000.00 | 651,454 | 2025-09-24 | Filing | |
| $41.69 | 5,022 | $209,367.18 | 711,454 | 2025-09-24 | Filing | |
| $40.68 | 49,978 | $2,033,105.04 | 716,476 | 2025-09-24 | Filing | |
| $40.04 | 60,000 | $2,402,400.00 | 766,454 | 2025-09-24 | Filing | |
| $39.59 | 51,316 | $2,031,600.44 | 826,454 | 2025-09-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 102,124 | $5,960,978 | 0.01% | |
| 2. | 87,054 | $5,081,342 | 0.67% | |
| 3. | 300 | $17,511 | 0% | |
| 4. | 165 | $9,632 | 0% | |
| 5. | 70 | $4,086 | 0% |
News See All
uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission
uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developing transformative treatments for severe medical conditions.
uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment
“We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntington’s disease,” said Uniqure NV (NASDAQ:QURE) Chief Medical Officer...
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington's Disease
Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as investors cheered stellar results from the clinical trial of its drug candidate for Huntington’s disease...
uniQure's AMT-130 Gene Therapy for Huntington's Disease on Track for Q1 2026 BLA Submission After FDA Alignment
uniQure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the uniQure Second Quarter 2025 Earnings Conference Call.
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Hedge Fund Resource Center Billionaire Hedge Funds
